Jupiter Neurosciences Selected as B2i Digital Featured Company

Clinical-Stage Pharmaceutical Company Advancing Phase IIa Parkinsons Trial

Dual-Path Strategy Targets Neuroinflammation While Expanding NugeviaTM Longevity Brand

NEW YORK, NY - February 12, 2026 (NEWMEDIAWIRE) - B2i Digital, Inc. , a capital markets positioning and investor connectivity platform focused on growth-stage public companies, today announced that Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has been selected as a B2i Digital Featured Company.

Jupiter Neurosciences is advancing a therapeutic pipeline targeting neuroinflammation and central nervous system (CNS) disorders, led by an FDA-cleared Phase IIa clinical trial in Parkinsons disease. The company is also exploring additional indications including Alzheimers disease, Friedreichs Ataxia, Mucopolysaccharidoses Type I, and MELAS, supported by research collaborations with Harvard University, Georgetown University, MITs Picower Institute, and the University of Miami.

Alongside its clinical program, Jupiter is expanding NugeviaTM, a consumer longevity brand powered by its proprietary JOTROLTM enhanced resveratrol formulation. This dual-path strategy combines clinical development with emerging commercial revenue pathways, creating a differentiated operating model as key milestones advance.

Jupiter Neurosciences offers investors a differentiated opportunity within the CNS sector, said David Shapiro, Chief Executive Officer of B2i Digital. With a Phase IIa Parkinsons trial underway and a consumer longevity platform already in market, the company is advancing its pipeline while building potential revenue streams. We look forward to expanding their visibility across our investor network.

We believe we are entering an important inflection point, said Christer Rosen, Founder, Chairman and CEO of Jupiter Neurosciences. As our Parkinsons program progresses and Nugevia continues to scale, partnering with B2i Digital strengthens our ability to communicate our story to the broader capital markets.

To learn more about Jupiter Neurosciences, visit www.jupiterneurosciences.com .

For investor inquiries, contact [email protected] .

About B2i Digital, Inc.

B2i Digital, Inc. is a capital markets positioning and investor connectivity platform serving growth-stage public companies. Through its Featured Conference, Featured Company, and Featured Expert programs, B2i Digital helps management teams sharpen their capital markets narrative and engage directly with active investors across the investor conference ecosystem.

Acting as The Capital Markets MatchmakerSM, B2i Digital leverages a proprietary network of more than 1.5 million capital markets participants and a curated email distribution of more than 100,000 investors and industry professionals to move companies from marketing to meaningful investor meetings. Its approach, captured in the mantra From Marketing to MeetingsSM, reflects a focus on measurable investor engagement. Founded in 2021 by former Maxim Group investment banker and Chief Marketing Officer David Shapiro, B2i Digital is headquartered in New York City.

B2i Digital Contact Information:

David Shapiro

Chief Executive Officer

B2i Digital, Inc.

https://b2idigital.com

212.579.4844 Office

[email protected]

https://www.linkedin.com/in/davidshapironyc

https://www.linkedin.com/company/b2i-digital

https://x.com/b2idigital

https://www.facebook.com/b2idigital

https://www.instagram.com/b2i_digital

https://www.youtube.com/@b2idigital

https://stocktwits.com/B2iDigital

https://www.reddit.com/user/b2idigital/

https://www.pinterest.com/b2idigital/

https://www.tiktok.com/@b2idigital

https://bsky.app/profile/b2idigital.bsky.social

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases while expanding into the consumer longevity market with its NugeviaTM product line. Both initiatives are powered by JOTROLTM, Jupiters proprietary enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. NugeviaTM brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Companys pipeline is focused broadly on CNS disorders and currently includes a Phase IIa clinical trial in Parkinsons disease, with additional exploration in Alzheimers disease, Mucopolysaccharidoses Type I, Friedreichs Ataxia, and MELAS.

More information may be found at www.jupiterneurosciences.com .

Contact Information:

Jupiter Neurosciences, Inc.

[email protected]

https://www.linkedin.com/company/jupiterneurosciences/

https://x.com/jupiterneuro

View the original release on www.newmediawire.com

Copyright 2026 JCN Newswire . All rights reserved.

You May Also Be Interested In

• Allison Brady resigns from Jupiter Neurosciences board
• Globee® Awards for Impact, Now in Its 19th Year, Invite Enterprise Technology Achievement Nominations from Professionals, Teams, and Departments Worldwide
• North American Pet Insurance Adoption Continues to Grow as 7.6 Million Pet Parents Seek Peace of Mind